Back to search
FDAFDA · Food and drugs·Recall number Z-0020-2015

Proteus 235 Proton Therapy System for cancer treatment.

Published November 5, 2014 · Recall initiated: March 27, 2014

Summary

FDA records medical device Class II recall Z-0020-2015, published November 5, 2014 and initiated March 27, 2014. Recalling firm: Ion Beam Applications S.A.; Status: Terminated; Reported quantity: 8; Lot: PAT.107, PAT.109, PAT.112, PAT.113, PAT.114, PAT.115, PAT.116, PAT.119. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

While the Proteus 235 is in the pencil beam scanning (PBS) treatment mode, on rare occasions, Low Level Radio Frequency (LLRF) pulsed dee voltage (i.e., voltage applied between two electrodes in the cyclotron to accelerate protons) may generate a hot spot on a pencil beam position within a tumor, generating a dose that might exceed the prescribed dose on a single voxel.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Ion Beam Applications S.A.
Distributor
Worldwide Distribution-USA (nationwide) including the states of PA, NJ, IL, WA, and TN, and the countries of Germany, Italy, and Czech Republic.
Lot
PAT.107, PAT.109, PAT.112, PAT.113, PAT.114, PAT.115, PAT.116, PAT.119.
Risk classification
Class II
Area (FDA)
device
Country
Belgium

Related recalls

Questions about this recall

Was Proteus 235 Proton Therapy System for cancer treatment. recalled?

Yes. FDA published recall Z-0020-2015 on November 5, 2014. Reported hazard: While the Proteus 235 is in the pencil beam scanning (PBS) treatment mode, on rare occasions, Low Level Radio Frequency (LLRF) pulsed dee voltage (i.e., voltage applied between two electrodes in the cyclotron to accelerate protons) may generate a hot spot on a pencil beam position within a tumor, generating a dose that might exceed the prescribed dose on a single voxel.

What should I do if I have this product?

Voluntary: Firm initiated · Letter